Introducing the Investigator Global Assessment of Hidradenitis Suppurativa (I-GLASS) instrument

To date, the primary endpoint of hidradenitis suppurativa (HS) clinical trials is typically a focused lesion count, which has been shown to be error prone and which may not comprehensively measure the inflammatory burden. Unlike lesions of other inflammatory skin diseases such as atopic dermatitis, vitiligo and alopecia areata, HS lesions exhibit substantial morphological heterogeneity. Accordingly, the Investigator Global Assessment of Hidradenitis Suppurativa (I-GLASS) instrument was developed.